Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
NGM120 for Pancreatic and Prostate Cancer
Recruiting0 awardsPhase 1 & 2
Nashville, Tennessee
This trial is testing NGM120, a new drug, in patients with advanced solid tumors, pancreatic cancer, and metastatic prostate cancer. The drug works by blocking signals that help cancer cells grow.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service